Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
176 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Kidney Transplantation - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Kidney Transplantation - Pipeline Review, H1 2016', provides an overview of the Kidney Transplantation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Kidney Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Transplantation and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Kidney Transplantation - The report reviews pipeline therapeutics for Kidney Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Kidney Transplantation therapeutics and enlists all their major and minor projects - The report assesses Kidney Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Kidney Transplantation Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Kidney Transplantation - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Kidney Transplantation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Kidney Transplantation Overview 11 Therapeutics Development 12 Pipeline Products for Kidney Transplantation - Overview 12 Pipeline Products for Kidney Transplantation - Comparative Analysis 13 Kidney Transplantation - Therapeutics under Development by Companies 14 Kidney Transplantation - Therapeutics under Investigation by Universities/Institutes 16 Kidney Transplantation - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Kidney Transplantation - Products under Development by Companies 21 Kidney Transplantation - Products under Investigation by Universities/Institutes 23 Kidney Transplantation - Companies Involved in Therapeutics Development 24 Alexion Pharmaceuticals, Inc. 24 Amgen Inc. 25 Amyndas Pharmaceuticals LLC 26 Angion Biomedica Corp. 27 Astellas Pharma Inc. 28 Bio-inRen 29 Catalyst Biosciences, Inc. 30 Corline Biomedical AB 31 CSL Limited 32 Digna Biotech, S.L. 33 Dompe Farmaceutici S.p.A. 34 Effimune SAS 35 FibroGen, Inc. 36 GlaxoSmithKline Plc 37 Grifols, S.A. 38 Hansa Medical AB 39 Kyowa Hakko Kirin Co., Ltd. 40 Mabtech Limited 41 Noorik Biopharmaceuticals AG 42 Novartis AG 43 Opsona Therapeutics Limited 44 Pharming Group N.V. 45 Prolong Pharmaceuticals, LLC 46 Quark Pharmaceuticals, Inc. 47 Shire Plc 48 t-cell Europe GmbH 49 Tiziana Life Sciences Plc 50 Zyrnat Biotherapeutics SL 51 Kidney Transplantation - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Target 53 Assessment by Mechanism of Action 55 Assessment by Route of Administration 57 Assessment by Molecule Type 59 Drug Profiles 61 albumin (human) - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 AMY-101 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 AS-2521780 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 basiliximab biobetter - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 BB-3 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 belimumab - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 bleselumab - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 BRN-1889 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 C1 esterase inhibitor (human) - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 C1 esterase inhibitor (human) - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 C1 esterase inhibitor (recombinant) - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Cardiotrophin-1 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 carfilzomib - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 CB-2782 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Cellular Immunotherapy for Kidney Transplant - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Cellular Immunotherapy for Kidney Transplantation - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Cellular Immunotherapy for Kidney Transplantation - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Cellular Immunotherapy for Multiple Sclerosis and Kidney Transplantation - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 CFZ-533 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 eculizumab - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 EFFI-7H - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 FCR-001 - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 FG-4497 - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 foralumab - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 FR-104 - Drug Profile 109 Product Description 109 Mechanism of Action 109 R&D Progress 109 FX-06 - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 111 Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 MRX-109 - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 N-003 - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 OPN-305 - Drug Profile 117 Product Description 117 Mechanism of Action 117 R&D Progress 117 QPI-1002 - Drug Profile 119 Product Description 119 Mechanism of Action 119 R&D Progress 119 Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - Drug Profile 121 Product Description 121 Mechanism of Action 121 R&D Progress 121 Renaparin - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 reparixin - Drug Profile 124 Product Description 124 Mechanism of Action 124 R&D Progress 124 Sanguinate - Drug Profile 126 Product Description 126 Mechanism of Action 126 R&D Progress 126 TNT-009 - Drug Profile 128 Product Description 128 Mechanism of Action 128 R&D Progress 128 ZY-11 - Drug Profile 129 Product Description 129 Mechanism of Action 129 R&D Progress 129 Kidney Transplantation - Recent Pipeline Updates 130 Kidney Transplantation - Dormant Projects 166 Kidney Transplantation - Discontinued Products 169 Kidney Transplantation - Product Development Milestones 170 Featured News & Press Releases 170 Apr 04, 2016: FDA clears Hansa Medical's IND application for IdeS in kidney transplantation 170 Mar 11, 2016: Study results presented in New England Journal of Medicine strengthen Hansa Medical belief in the potential of IdeS 170 Dec 07, 2015: True North Therapeutics Presents Data in Patients with Cold Agglutinin Disease Supporting Patient Profiles for TNT009 Phase 1b Study 171 Nov 13, 2015: Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies 171 Nov 10, 2015: Data showing that IdeS can silence memory B-cells published in Journal of Immunology 172 Oct 30, 2015: Licensee's drug to commence Phase 2 and Phase 3 trials 172 Oct 13, 2015: Shire's CINRYZE (C1 esterase inhibitor [human]) Receives FDA Fast Track Designation for Investigation in the Treatment of Antibody Mediated Rejection in Patients Receiving Kidney Transplants 172 Sep 15, 2015: Data from Hansa Medical's First Phase II study of IdeS in Sensitized Kidney Transplantation Patients Presented in Oral Session at ESOT 2015 173 Sep 14, 2015: Hansa Medical receives FDA Orphan Drug Designation for IdeS 173 Appendix 175 Methodology 175 Coverage 175 Secondary Research 175 Primary Research 175 Expert Panel Validation 175 Contact Us 175 Disclaimer 176
List of Tables
Number of Products under Development for Kidney Transplantation, H1 2016 12 Number of Products under Development for Kidney Transplantation - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Number of Products under Development by Companies, H1 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Development, H1 2016 19 Comparative Analysis by Unknown Stage Development, H1 2016 20 Products under Development by Companies, H1 2016 21 Products under Development by Companies, H1 2016 (Contd..1) 22 Products under Investigation by Universities/Institutes, H1 2016 23 Kidney Transplantation - Pipeline by Alexion Pharmaceuticals, Inc., H1 2016 24 Kidney Transplantation - Pipeline by Amgen Inc., H1 2016 25 Kidney Transplantation - Pipeline by Amyndas Pharmaceuticals LLC, H1 2016 26 Kidney Transplantation - Pipeline by Angion Biomedica Corp., H1 2016 27 Kidney Transplantation - Pipeline by Astellas Pharma Inc., H1 2016 28 Kidney Transplantation - Pipeline by Bio-inRen, H1 2016 29 Kidney Transplantation - Pipeline by Catalyst Biosciences, Inc., H1 2016 30 Kidney Transplantation - Pipeline by Corline Biomedical AB, H1 2016 31 Kidney Transplantation - Pipeline by CSL Limited, H1 2016 32 Kidney Transplantation - Pipeline by Digna Biotech, S.L., H1 2016 33 Kidney Transplantation - Pipeline by Dompe Farmaceutici S.p.A., H1 2016 34 Kidney Transplantation - Pipeline by Effimune SAS, H1 2016 35 Kidney Transplantation - Pipeline by FibroGen, Inc., H1 2016 36 Kidney Transplantation - Pipeline by GlaxoSmithKline Plc, H1 2016 37 Kidney Transplantation - Pipeline by Grifols, S.A., H1 2016 38 Kidney Transplantation - Pipeline by Hansa Medical AB, H1 2016 39 Kidney Transplantation - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 40 Kidney Transplantation - Pipeline by Mabtech Limited, H1 2016 41 Kidney Transplantation - Pipeline by Noorik Biopharmaceuticals AG, H1 2016 42 Kidney Transplantation - Pipeline by Novartis AG, H1 2016 43 Kidney Transplantation - Pipeline by Opsona Therapeutics Limited, H1 2016 44 Kidney Transplantation - Pipeline by Pharming Group N.V., H1 2016 45 Kidney Transplantation - Pipeline by Prolong Pharmaceuticals, LLC, H1 2016 46 Kidney Transplantation - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 47 Kidney Transplantation - Pipeline by Shire Plc, H1 2016 48 Kidney Transplantation - Pipeline by t-cell Europe GmbH, H1 2016 49 Kidney Transplantation - Pipeline by Tiziana Life Sciences Plc, H1 2016 50 Kidney Transplantation - Pipeline by Zyrnat Biotherapeutics SL, H1 2016 51 Assessment by Monotherapy Products, H1 2016 52 Number of Products by Stage and Target, H1 2016 54 Number of Products by Stage and Mechanism of Action, H1 2016 56 Number of Products by Stage and Route of Administration, H1 2016 58 Number of Products by Stage and Molecule Type, H1 2016 60 Kidney Transplantation Therapeutics - Recent Pipeline Updates, H1 2016 130 Kidney Transplantation - Dormant Projects, H1 2016 166 Kidney Transplantation - Dormant Projects (Contd..1), H1 2016 167 Kidney Transplantation - Dormant Projects (Contd..2), H1 2016 168 Kidney Transplantation - Discontinued Products, H1 2016 169
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
